Abstract
We conducted a phase II study to evaluate the antitumor activity and safety of concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer (NSCLC). Cisplatin (30 mg/m2 daily) and etoposide (80 mg/m2 daily) were given as a 24-h continuous infusion for 72 h to 48 patients with previously untreated advanced NSCLC. Of the 46 evaluable patients, 9 achieved a partial response, for an overall response rate of 20% (95% confidence interval, 9.4%–33.9%). The median duration of response was 23 weeks. The median duration of survival for all patients was 34.4 weeks. The major toxicity was hematologic. Leukopenia (WHO grade ≥3) was observed in 22 patients (48%) and thrombocytopenia (WHO grade ≥3), in 13 patients (28%). In all, 20 patients (43%) experienced severe anemia (WHO grade ≥3). Nonhematologic toxicity mainly consisted of moderate to severe alopecia in 33 patients (72%) and moderate to severe nausea and vomiting in 25 patients (54%). No sigificant nephrotoxicity was seen. We conclude that a 72-h concurrent continuous infuson of cisplatin and etoposide does not appear to be active against advanced NSCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bakowski MT, Crouch JC (1983) Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future Cancer Treat Rev 10: 159
Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, O'Leary GP Jr, Griffin H, Phaneuf MA, O'Rourke A, Calabresi P (1986) Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat Rep 70: 1215
Cavalli E, Sonntag RW, Jungi F Senn HJ, Brunner KW (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62: 474
Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R (1990) Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma. Cancer Chemother Pharmacol 26: 365
Drewinko B, Brown BW, Gottlieb JA (1973) The effect ofcis-diamminedichloroplatinum(II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 33: 3091
Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP Jr (1988) Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent boluscis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res 48: 3869
Goldberg RM, Jett JR, Therneau TM, Johnson PS, Tschetter LK, Krook JE, Veeder MH, Owen D, Etzell PS, Andres DF (1990) Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment Group. J Natl Cancer Inst 82: 1899
Kaplan EL, Meier P (1958) Nonparametric estimation fron incomplete observations. Am Stat Assoc J 53: 457
Klastersky J (1986) Therapy with cisplatin and etoposide for non-small-cell lung cancer. Semin Oncol 13 [Suppl]: 104
Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle Y, Mairesse M, Michiels T, Thiriaux J, Mommen P, Dalesio O, the EORTC Lung Cancer Working Party (1986) A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4: 1780
Krook JE, Jett JR, Little C (1989) A phase I-II study of sequential infusion of VP-16 and cisplatin therapy in advanced lung cancer. Am J Clin Oncol 12: 114
Marechal F, Berthiot G, Cattan A (1990) Five-day continuous infusion of cisplatin and etoposide in non-small cell lung cancer. A phase II trial. Acta Oncol 29: 989
Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N (1985) Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14: 104
Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP (1979)cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459
Sierocki JS, Hilaris BS, Hopfan S, Martini N, Barton D, Golbey RB, Wittes RE (1979)cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction reginmen for small cell carcinoma of the lung. Cancer Treat Rep 63: 1593
Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333
Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA (1992) Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol 10: 292
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication 48, World Health Organization, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saito, H., Shimokata, K., Yamamoto, M. et al. Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 32, 134–136 (1993). https://doi.org/10.1007/BF00685616
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685616